Risk factors for development of aminoglycoside resistance among gram-negative rods.
Academic Medical Centers
Adult
Aged
Aged, 80 and over
Algorithms
Aminoglycosides
/ pharmacology
Anti-Bacterial Agents
/ pharmacology
Antimicrobial Stewardship
Carbapenems
/ therapeutic use
Drug Resistance, Bacterial
Female
Gram-Negative Bacteria
/ drug effects
Gram-Negative Bacterial Infections
/ drug therapy
Humans
Male
Middle Aged
Patient Transfer
Respiration, Artificial
Retrospective Studies
Risk Factors
Sex Factors
Weight Loss
Young Adult
aminoglycosides
antimicrobial resistance
antimicrobial stewardship
clinical decision making
gram-negative rods
Journal
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
ISSN: 1535-2900
Titre abrégé: Am J Health Syst Pharm
Pays: England
ID NLM: 9503023
Informations de publication
Date de publication:
30 10 2019
30 10 2019
Historique:
entrez:
31
10
2019
pubmed:
31
10
2019
medline:
11
3
2020
Statut:
ppublish
Résumé
Development of scoring systems to predict the risk of aminoglycoside resistance and to guide therapy is described. Infections due to aminoglycoside-resistant gram-negative rods (AR-GNRs) are increasingly common and associated with adverse outcomes; selection of effective initial antibiotic therapy is necessary to reduce adverse consequences and shorten length of stay. To determine risk factors for AR-GNR recovery from culture, cases of GNR infection among patients admitted to 2 institutions in a major academic hospital system during the period 2011-2016 were retrospectively analyzed. Gentamicin and tobramycin resistance (GTR-GNR) and amikacin resistance (AmR-GNR) patterns were analyzed separately. A total of 26,154 GNR isolates from 12,516 patients were analyzed, 6,699 of which were GTR, and 2,467 of which were AmR. In multivariate analysis, risk factors for GTR-GNR were presence of weight loss, admission from another medical or long-term care facility, a hemoglobin level of <11 g/dL, receipt of any carbapenem in the prior 30 days, and receipt of any fluoroquinolone in the prior 30 days (C statistic, 0.63). Risk factors for AmR-GNR were diagnosis of cystic fibrosis, male gender, admission from another medical or long-term care facility, ventilation at any point prior to culture during the index hospitalization, receipt of any carbapenem in the prior 30 days, and receipt of any anti-MRSA agent in the prior 30 days (C statistic, 0.74). Multinomial and ordinal models demonstrated that the risk factors for the 2 resistance patterns differed significantly. A scoring system derived from the developed risk prediction models can be applied by providers to guide empirical antimicrobial therapy for treatment of GNR infections.
Identifiants
pubmed: 31665763
pii: 5609624
doi: 10.1093/ajhp/zxz201
pmc: PMC7170722
doi:
Substances chimiques
Aminoglycosides
0
Anti-Bacterial Agents
0
Carbapenems
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1838-1847Subventions
Organisme : NHLBI NIH HHS
ID : T32 HL007895
Pays : United States
Organisme : NIGMS NIH HHS
ID : U54 GM114833
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001881
Pays : United States
Informations de copyright
© American Society of Health-System Pharmacists 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
JAMA. 2003 Feb 19;289(7):885-8
pubmed: 12588273
Crit Care Med. 2011 Jan;39(1):46-51
pubmed: 20890186
Med Care. 2009 Jun;47(6):626-33
pubmed: 19433995
Arch Intern Med. 2008 Nov 10;168(20):2205-10
pubmed: 19001196
BMC Infect Dis. 2015 Sep 30;15:395
pubmed: 26423743
Curr Opin Infect Dis. 2013 Dec;26(6):516-25
pubmed: 24141453
Open Microbiol J. 2017 May 31;11:92-97
pubmed: 28694882
Clin Infect Dis. 2004 Aug 15;39(4):497-503
pubmed: 15356812
J Antimicrob Chemother. 2008 Nov;62(5):1130-7
pubmed: 18635519
Crit Care Med. 2006 Jun;34(6):1589-96
pubmed: 16625125
Eur J Clin Microbiol Infect Dis. 1999 Jun;18(6):414-21
pubmed: 10442419
Chest. 1999 Feb;115(2):462-74
pubmed: 10027448
Am J Med. 1985 Jul 15;79(1A):1-7
pubmed: 4025364
Clin Microbiol Infect. 2001 Sep;7(9):470-8
pubmed: 11678929
J Chemother. 2014 Feb;26(1):19-25
pubmed: 24090698
BMC Infect Dis. 2008 Sep 15;8:116
pubmed: 18793400
Biomed Pharmacother. 2008 Jan;62(1):53-8
pubmed: 18083323
Emerg Med J. 2003 Jan;20(1):54-60
pubmed: 12533370
Antimicrob Agents Chemother. 2005 Feb;49(2):479-87
pubmed: 15673721
Clin Microbiol Infect. 2007 Mar;13(3):269-76
pubmed: 17391381
Expert Rev Anti Infect Ther. 2013 Oct;11(10):1053-63
pubmed: 24073806
PLoS One. 2015 Oct 02;10(10):e0139883
pubmed: 26431402
J Infect. 2011 Feb;62(2):159-64
pubmed: 21055417
PLoS One. 2015 Dec 28;10(12):e0145088
pubmed: 26710322
Arch Intern Med. 1989 Jun;149(6):1397-401
pubmed: 2730257
Antimicrob Agents Chemother. 1991 Jul;35(7):1284-90
pubmed: 1929283
J Clin Epidemiol. 1996 Dec;49(12):1373-9
pubmed: 8970487
Postgrad Med J. 1999 Jun;75(884):342-5
pubmed: 10435168